CYTK Cytokinetics, Incorporated

Cytokinetics (NASDAQ:CYTK) executives outlined the company’s commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure. Isaac Ciecha

Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]

Cytokinetics (CYTK) likely has the upper hand in its patent dispute with Bristol-Myers Squibb (BMY)

Cytokinetics, Incorporated (NASDAQ:CYTK) has reported detailed late-stage results that could support an expansion of aficamten into a form of genetic heart disease that currently does not have any approved treatments. Aficamten is already approved under the brand name Myqorzo for obstructive hypertrophic cardiomyopathy, or oHCM, in which thickened heart muscle restricts blood flow. Cytokinetics (NASDAQ:CYTK) […]

Cytokinetics' aficamten shows added benefits in HCM studies, strengthening its potential in non-obstructive and obstructive disease.

Cytokinetics (CYTK) is back in focus after presenting new Phase 3 data for aficamten in hypertrophic cardiomyopathy at the European Society of Cardiology Congress 2026, alongside plans for a supplemental FDA filing. Cytokinetics shares have been under pressure in recent weeks, with the 7 day share price return down 8.46% and the 30 day share price return down 8.06%, even as the stock posts a year to date share price gain of 14.87% and a 1 year total shareholder return of 42.91%. This suggests...

Cytokinetics (NasdaqGS: CYTK) reports positive Phase 3 results for aficamten (MYQORZO) in patients with symptomatic non-obstructive hypertrophic cardiomyopathy. The trial is described as the first successful clinical study in this indication, with results presented at a major cardiology conference and published in leading medical journals. Cytokinetics plans to submit a supplemental New Drug Application seeking an expanded label for aficamten in non-obstructive hypertrophic...

Investing.com -- Jefferies initiated coverage of Braveheart Bio with a Buy rating and a $48 price target, implying roughly 75% upside from the stock’s prior closing price. The move comes after the company priced its initial public offering (IPO) at $18 per share earlier this month, raising $382.5 million in one of the largest biotech debuts of 2026.

At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.

Cytokinetics scored the first-ever win for a Phase 3 study in non-obstructive hypertrophic cardiomyopathy on Friday.

Cytokinetics (NASDAQ:CYTK) presented primary results from its Phase III ACACIA-HCM trial evaluating aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, or nHCM, reporting that the study met its dual primary endpoints for patient-reported health status and exercise cap

Blum exercised stock options at $10.60 and sold at $76.76, capturing significant appreciation.

Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.

The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.

MYQORZO captures 40% new-to-brand share with 1,500 dispensed patients.

Cytokinetics stock has delivered strong multi year returns, yet its latest valuation checks point to a more mixed picture rather than a clear bargain or an obvious overvaluation. Cytokinetics has returned about 139% over the past 5 years, which puts extra focus on whether current holders are still being fairly compensated for the risks they are taking. The recent UK approval and reimbursement support for MYQORZO may support investor expectations for future revenue, while ongoing regulatory...

CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.

Moby summary of Cytokinetics, Incorporated's Q2 2026 earnings call

Strong US commercial uptake and positive Phase 3 data position Cytokinetics for expanded market leadership in HCM treatment.

Cytokinetics (NASDAQ:CYTK) reported second-quarter results marked by early commercial momentum for MYQORZO, international market-access progress and plans to seek an expanded indication for aficamten in non-obstructive hypertrophic cardiomyopathy, or nHCM. Chief Executive Officer Robert Blum said t

Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cytokinetics (CYTK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Cytokinetics (CYTK) points to a 30.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Blum exercised options at $10.60 per share and immediately sold them at $82.02, capturing gains from a 122% stock surge over the past year. He retains 381,986 shares and maintains a 0.31% ownership stake.